45525 (CUR.TO) - CUR Stock Price Target and Predictions

  • Consensus Rating: Buy
  • Consensus Price Target: C$3.00
  • Forecasted Upside:
  • Number of Analysts: 1
  • Breakdown:
  • 0 Sell Ratings
  • 0 Hold Ratings
  • 1 Buy Ratings
  • 0 Strong Buy Ratings
C$0.00
+0 (0.00%)

This chart shows the closing price for CUR by one month, three months, or twelve months.

Skip Closing Price Chart
1 month | 3 months | 12 months
Get New 45525 (CUR.TO) Analyst Ratings Delivered To Your Inbox
Sign-up to receive the latest news and ratings for CUR and its competitors with Analyst Ratings Network’s free daily newsletter.

Analyst Price Target for CUR

Analyst Price Target is C$3.00
▲ +∞ Upside Potential
This price target is based on 1 analysts offering 12 month price targets for 45525 (CUR.TO) in the last 3 months. The average price target is C$3.00, with a high forecast of C$3.00 and a low forecast of C$3.00. The average price target represents a ∞ upside from the last price of C$0.00.

This chart shows the closing price for CUR for the last year in relation to the current analyst high, average, and low pricetarget.

Read Analyst Price Chart DescriptionSkip Analyst Price Chart




Current Consensus is Buy

The current consensus among 1 polled investment analysts is to buy stock in 45525 (CUR.TO). This Buy consensus rating has held steady for over two years.

Past Monthly Recommendations

Move your mouse over past months for details

Read Past Recommendations DescriptionSkip Past Price Target Consensus Chart
  • 0 strong buy ratings
  • 1 buy ratings
  • 0 hold ratings
  • 0 sell ratings
1/1/2023
  • 0 strong buy ratings
  • 1 buy ratings
  • 0 hold ratings
  • 0 sell ratings
4/1/2023
  • 0 strong buy ratings
  • 1 buy ratings
  • 0 hold ratings
  • 0 sell ratings
6/30/2023
  • 0 strong buy ratings
  • 1 buy ratings
  • 0 hold ratings
  • 0 sell ratings
9/28/2023
  • 0 strong buy ratings
  • 1 buy ratings
  • 0 hold ratings
  • 0 sell ratings
12/27/2023
  • 0 strong buy ratings
  • 1 buy ratings
  • 0 hold ratings
  • 0 sell ratings
3/26/2024
  • 0 strong buy ratings
  • 1 buy ratings
  • 0 hold ratings
  • 0 sell ratings
5/25/2024
  • 0 strong buy ratings
  • 1 buy ratings
  • 0 hold ratings
  • 0 sell ratings
6/24/2024

Latest Recommendations

  • 0 strong buy ratings
  • 1 buy ratings
  • 0 hold ratings
  • 0 sell ratings

Display Ratings By
DateBrokerageActionRatingPrice TargetDetails
7/18/2023Haywood SecuritiesSet TargetBuyC$3.00
(Data available from 6/24/2019 forward)

News Sentiment Rating

Our news sentiment rating is based on the average sentiment of articles about this company published in the media in the last 30 days of headlines and can range from 2 (very positive sentiment) to -2 (very negative sentiment).

News Sentiment Over Time

Move your mouse over past months for details

Skip to Current Sentiment Summary
  • 0 very positive mentions
  • 0 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
11/27/2023
  • 0 very positive mentions
  • 1 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
12/27/2023
  • 1 very positive mentions
  • 0 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
1/26/2024
  • 0 very positive mentions
  • 1 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
2/25/2024
  • 0 very positive mentions
  • 0 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
3/26/2024
  • 0 very positive mentions
  • 1 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
4/25/2024
  • 0 very positive mentions
  • 1 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
5/25/2024
  • 0 very positive mentions
  • 0 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
6/24/2024

Current Sentiment

  • 0 very positive mentions
  • 0 positive mentions
  • 0 negative mentions
  • 0 very negative mentions

Recent Stories by Sentiment

Very Negative

  • No very negative mentions tracked during this time.

Negative

  • No negative mentions tracked during this time.

Positive

  • No positive mentions tracked during this time.

Very Positive

  • No very positive mentions tracked during this time.
45525 (CUR.TO) logo
9342-8530 Quebec Inc, formerly Diagnocure Inc, is a Canada-based biotechnology company. The Company specializes in the development and commercialization of products relating to the diagnosis of cancer. It intends to focus its activities on business development efforts by out-licensing, selling or partnering with third parties with regards to its Previstage GCC and its new multimarker prostate cancer test (PCP). The Company's colorectal cancer staging test, Previstage GCC, uses the Guanylyl Cyclase C (GCC or GUCY2C) marker to stratify the risk of colon cancer recurrence by determining the stage of the disease. Previstage GCC Colorectal Cancer Staging test is a molecular test for the staging of colorectal cancer patients. The PROGENSA PCA3 assay is a molecular urine test that can be used as a predictor of biopsy outcome in men with a serum prostate specific antigen (PSA) level over 2.5 nanograms per milliliter (ng/ml).
Read More

Today's Range

Now: N/A

50 Day Range

MA: N/A

52 Week Range

Now: N/A

Volume

N/A

Average Volume

130,253 shs

Market Capitalization

N/A

P/E Ratio

N/A

Dividend Yield

N/A

Beta

N/A

Frequently Asked Questions

What sell-side analysts currently cover shares of 45525 (CUR.TO)?

The following Wall Street research analysts have issued reports on 45525 (CUR.TO) in the last twelve months: Haywood Securities.
View the latest analyst ratings for CUR.

What is the current price target for 45525 (CUR.TO)?

1 Wall Street analysts have set twelve-month price targets for 45525 (CUR.TO) in the last year. Their average twelve-month price target is C$3.00. Haywood Securities has the highest price target set, predicting CUR will reach C$3.00 in the next twelve months. Haywood Securities has the lowest price target set, forecasting a price of C$3.00 for 45525 (CUR.TO) in the next year.
View the latest price targets for CUR.

What is the current consensus analyst rating for 45525 (CUR.TO)?

45525 (CUR.TO) currently has 1 buy rating from Wall Street analysts. The stock has a consensus analyst rating of "Buy." A "buy" rating indicates that analysts believe CUR will outperform the market and that investors should add to their positions of 45525 (CUR.TO).
View the latest ratings for CUR.

How do I contact 45525 (CUR.TO)'s investor relations team?

45525 (CUR.TO)'s physical mailing address is 250-4535 Wilfrid-Hamel Blvd, QUEBEC, QC G1P 2J7, Canada. The biotechnology company's listed phone number is +1-418-5276100. The official website for 45525 (CUR.TO) is www.neuralstem.com. Learn More about contacing 45525 (CUR.TO) investor relations.